Upload File

biosimilar education

1

Upload: industry-standard-research

Post on 22-Apr-2015

537 views

Category:

Documents


0 download

Report

DESCRIPTION

In this infographic, ISR explores what US patients know about Biologic and Biosimilar Medicines, who they’re consulting to make decisions, and how a small amount of information can affect that.

TRANSCRIPT

Page 1: Biosimilar Education

Biosimilar - a mAb case study

A STREAMLINED ANALYTICAL PLATFORM FOR GLYCAN … · Biosimilar Biosimilar Biosimilar Biosimilar Biosimilar Biosimilar Biosimilar Biosimilar Sample Names Innovator Biosimilar Samples

CISummit 2013: Steve Gullans & Gregory Gallo, The BioSimilar Age: How to Promote a Biosimilar and Defend a Franchise from a BioSimilar Attack

published biosimilar AMWA aug2016

EGA Handbook on Biosimilar Medicines

Towards biosimilar monoclonal antibodies Pros and cons · Towards biosimilar monoclonal antibodies Pros and cons EMEA Workshop on Biosimilar Monoclonal Antibodies Christian K Schneider,

Biosimilar - A Purview

Rituximab Biosimilar Brochure

MARKET REVIEW – BIOSIMILAR MEDICINES MARKETS · The Biosimilar Medicines Group - Market Access Committee is pleased to present the 2017 Market Review – European Biosimilar Medicines

Filgrastim Biosimilar Brochure

Clinical Immunogenicity and the Biosimilar paradigm - …€¦ · Clinical Immunogenicity and the Biosimilar paradigm ... biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB

China Biosimilar

OTC & Biosimilar Directory 2010

The New India Biosimilar Guidelines

A Global View of Biosimilar Medicines · A Global View of Biosimilar Medicines EU ... avings potential in biosimilar accessible market at different price levels is calculated based

Biosimilar PK Guidance and Novel Approaches - BioClin Labsbioclinlabs.com/wp-content/uploads/2016/05/Biosimilar-PK-Guidance... · Biosimilar PK Guidance and Novel Approaches Dr Alison

Questions and Answers on Biosimilar Medicines · 1 Update of biosimilar Q&A Q&A on biosimilar medicines • Published in 2008 • In consultation with patient and consumer representatives

Biosimilar Comparability

2021 BIOSIMILAR TRENDS REPORT

Biosimilar Products

April 2020 - XBrane · 3 XBRANE BIOPHARMA –THE ONLY NORDIC BIOSIMILAR DEVELOPER Low-risk high potential lead phase III biosimilar •Xlucane (Lucentis®biosimilar) is a low-riskproduct

Towards biosimilar monoclonal antibodies Pros … biosimilar monoclonal antibodies Pros and cons EMEA Workshop on Biosimilar Monoclonal Antibodies Christian K Schneider, MD BMWP Chairman

[Product Monograph Template - Standard]€¦ · Web view is a biosimilar biologic drug (biosimilar) to

Biosimilar Biological Products

MARKET REVIEW – BIOSIMILAR MEDICINES … Biosimilar Medicines Group - Market Access Committee is pleased to present the 2017 Market Review – European Biosimilar Medicines Markets

TGA pharmacovigilance for biosimilar medicines · TGA pharmacovigilance for biosimilar medicines Biosimilar Awareness Initiative Reference Group ... Pharmacovigilance and Special

Biyobenzer İlaçlar Biosimilar Drugs

Biosimilar Clinical Challenges

Eurofins Biosimilar Trastuzumab Bioanalytics

TGA pharmacovigilance for biosimilar medicines · TGA pharmacovigilance for biosimilar medicines Biosimilar Awareness Initiative Reference Group Meeting- 29 November 2016. Dr Bronwen

Biosimilar Regulation in the ASEAN

Biosimilars digital mag - Canadian Breast Cancer Network · A DIGITAL EDUCATION SERIES. 2 LEARNING MORE ABOUT BIOSIMILAR TREATMENT OPTIONS What is a biosimilar? In short, a biosimilar

TGA pharmacovigilance for biosimilar medicines · 2019-12-29 · TGA pharmacovigilance for biosimilar medicines Biosimilar Awareness Initiative Reference Group Meeting- 29 November

The Impact of Biosimilar Competition

The new-india-biosimilar-guidelines